We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy. A 65-year-old male was diagnosed with prostate cancer (T4 N1 M1b). He received androgen-ablation therapy. But six months later he was confirmed to show failure of the previous hormone therapy and disease progression even after anti-androgen withdrawal. Then docetaxel plus prednisolone therapy was started. After two courses of this therapy, the PSA level decreased by 50% or more, and after ten courses an improvement was seen on the bone scan. The patient has survived for twelve months after starting docetaxel plus prednisolone therapy, without serious adverse events.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.
Oncologist
October 2024
EVERSANA™, Burlington, ON, Canada L7N 3H8.
Background: Talazoparib plus enzalutamide (TALA + ENZA) has demonstrated antitumor activity in the phase 3 clinical trial (TALAPRO-2; NCT03395197) as first-line (1L) therapy in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC). Although many active interventions are available, randomized controlled trials (RCTs) involving talazoparib have only been conducted to assess its efficacy and safety compared to enzalutamide. To estimate comparisons between all relevant interventions, indirect comparisons are needed.
View Article and Find Full Text PDFSynergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo.
Anticancer Drugs
January 2025
Department of Pharmacy, Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo Medical University, Kobe.
Prostate cancer antigen-1/ALKBH3, a DNA/RNA demethylase of 3-methylcytosine, 1-methyladenine (1-meA), and 6-meA, was found in prostate cancer as an important prognostic factor. Additionally, 1-meA has been associated with other cancers. The ALKBH3 inhibitor HUHS015 was found to be effective against prostate cancer both in vitro and in vivo .
View Article and Find Full Text PDFEctopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature.
Oncol Lett
September 2024
Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cushing's syndrome (CS), as a result of ectopic adrenocorticotropic hormone (ACTH) production, constitutes a common paraneoplastic manifestation of various malignancies, with the most common being small cell lung carcinoma. In the literature, fewer than fifty cases associating ectopic CS with prostate cancer have been documented. In the present study, the case of a 76-year old man suffering from castration-resistant prostate adenocarcinoma that had been treated with enzalutamide and luteinizing hormone-releasing hormone (LHRH) analogue for the last four years is presented.
View Article and Find Full Text PDFClinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Eur Urol Oncol
June 2024
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan.
Article Synopsis
- Androgen deprivation therapy (ADT), including combined androgen blockade (CAB) and ADT with ARSIs or docetaxel, is the standard treatment for metastatic hormone-naïve prostate cancer in Japan.
- A study analyzed treatment patterns and clinical outcomes in patients classified as high-risk under the LATITUDE criteria by splitting them into two cohorts: those receiving ADT or CAB, and those receiving ADT plus ARSIs or docetaxel.
- Results showed that the cohort receiving ADT plus ARSIs or docetaxel had significantly better outcomes regarding PSA response, progression-free survival, time to castrate-resistant prostate cancer, and overall survival compared to the cohort receiving only ADT or CAB, although limitations in study design were
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Clin Genitourin Cancer
April 2024
Department of Urology, Medical University Innsbruck, Innsbruck, Austria. Electronic address:
Article Synopsis
- Two randomized trials have established that triplet therapy (androgen deprivation therapy, ARPI, and docetaxel) provides better survival rates compared to doublet therapy (ADT and docetaxel) for patients with metastatic hormone-sensitive prostate cancer.
- A real-world analysis involving 97 mHSPC patients from various Austrian centers was conducted, tracking treatment responses and clinical parameters, while certain guideline-based treatments were underutilized in a significant percentage of the patients.
- Findings showed that patients who started ARPI after chemotherapy had better treatment responses, while 61.9% experienced adverse events, yet all patients had a notable decline in PSA levels, indicating treatment effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!